2023
Evolving Therapeutic Roles of Nasogastric Tubes: Current Concepts in Clinical Practice
Vadivelu N, Kodumudi G, Leffert L, Pierson D, Rein L, Silverman M, Cornett E, Kaye A. Evolving Therapeutic Roles of Nasogastric Tubes: Current Concepts in Clinical Practice. Advances In Therapy 2023, 40: 828-843. PMID: 36637690, PMCID: PMC9838367, DOI: 10.1007/s12325-022-02406-9.Peer-Reviewed Original ResearchConceptsNasogastric tubeShort-term parenteral nutritionTerm parenteral nutritionManagement of complicationsAdministration of medicationsMultiple medical specialtiesTechnique of insertionResuscitative toolBowel obstructionParenteral nutritionChronic careTherapeutic roleClinical practiceComplicationsSurgical specialtiesCurrent conceptsMedical specialtiesRecent updatesCorrect positioningSpecialtiesContraindicationsMedicationsObstructionStomachAdministration
2011
IFN-γ Acts on the Airway Epithelium To Inhibit Local and Systemic Pathology in Allergic Airway Disease
Mitchell C, Provost K, Niu N, Homer R, Cohn L. IFN-γ Acts on the Airway Epithelium To Inhibit Local and Systemic Pathology in Allergic Airway Disease. The Journal Of Immunology 2011, 187: 3815-3820. PMID: 21873527, PMCID: PMC3178669, DOI: 10.4049/jimmunol.1100436.Peer-Reviewed Original ResearchConceptsAirway epitheliumAllergic airway inflammationAllergic airway diseaseTh2 cell activationGoal of therapyProduction of IFNAdministration of medicationsSystemic side effectsAirway mucosal surfaceAirway epithelial cellsSites of inflammationIFN-γ actionAirway inflammationAirway obstructionPersistent asthmaRefractory asthmaAirway diseaseIFN-γRTh1 cellsPathological responseSystemic pathologyEffector functionsSide effectsBone marrowAsthma
2001
Cerebral blood flow in obsessive–compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders
Hoehn-Saric R, Schlaepfer T, Greenberg B, McLeod D, Pearlson G, Wong S. Cerebral blood flow in obsessive–compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders. Psychiatry Research 2001, 108: 89-100. PMID: 11738543, DOI: 10.1016/s0925-4927(01)00114-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood Flow VelocityCerebral CortexDepressive Disorder, MajorDesipramineDominance, CerebralDouble-Blind MethodFemaleHumansImage Processing, Computer-AssistedMaleMiddle AgedObsessive-Compulsive DisorderRegional Blood FlowSertralineTomography, Emission-Computed, Single-PhotonTreatment OutcomeConceptsRegional cerebral blood flowHigher regional cerebral blood flowWeeks of treatmentCerebral blood flowYale-Brown Obsessive Compulsive ScaleBlood flowTemporal regionsType of medicationEffects of sertralineMajor depressive episodePrefrontal regional cerebral blood flowAdministration of medicationsPrefrontal regionsHMPAO SPECT scansEffect of treatmentObsessive Compulsive ScaleDiffuse reductionRCBF reductionStudy entryBasal gangliaDepressive episodeClinical changesMajor depressionDrug treatmentTreatment responders
1982
Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate.
Shaywitz S, Hunt R, Jatlow P, Cohen D, Young J, Pierce R, Anderson G, Shaywitz B. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. 1982, 69: 688-94. PMID: 7079034, DOI: 10.1542/peds.69.6.688.Peer-Reviewed Original ResearchConceptsAcute studyMPH concentrationsGrowth hormoneObserved maximal concentrationCentral dopaminergic mechanismsPeak plasma concentrationAdministration of medicationsPharmacokinetics of methylphenidatePlasma growth hormoneConcentrations of methylphenidatePlasma MPH concentrationsAttention deficit disorderClinical responseChronic treatmentDopaminergic mechanismsGroup of childrenDisorders of attentionAbbreviated Conners' Rating ScaleSchool-aged childrenOral administrationPlasma concentrationsClinical pharmacologyMPH administrationProlactin concentrationsPercentage of improvement
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply